77.1% of patients on semaglutide achieved more than 5% weight loss, compared to 34.4% on placebo
These statements involve known and unknown risks, uncertainties and other factors which are not exhaustive
Lancet Diabetes Endocrinol (2020) 8(2):10614
Author of Inside Americas Opioid Crisis | Former Acting Drug Czar | Georgetown Professor Overdose deaths are falling, but America's illicit drug supply is re-engineering itself into lethal cocktails: fentanyl plus stimulants, sedatives, and novel synthetics that hide in party powders and pressed pills
Resources We Trust Mayo Clinic: Pros and Cons of GLP-1 Agonists for Weight Loss GLP-1 Weight-Loss Pills: What You Need to Know Yale Medicine: Johns Hopkins Medicine: The Pros, Cons, and Unknowns of Popular Weight Loss Drugs UCDavis Health: GLP-1 and Health: Beyond Weight Loss in the Ozempic Era Mount Sinai Today: What Are the Benefits of the New GLP-1 Weight Loss Pills
In that trial, 4,286 (24.3%) of patients had heart failure with 1,347 of those patients having heart failure with reduced ejection fraction dwarfing the small numbers studied in the initial trials mentioned previously
